Drug Profile
Bacterial lysate - Lallemand Pharma
Alternative Names: Antibacterial vaccine sublingual - Lallemand Pharma; Bactovax; Bromunyl; GSK-3966271A; Immubron; Ismigen; PIR-05; PMBL - Lallemand Pharma; Polyvalent Bacterial Mechanical Lysate - Lallemand Pharma; Provax; Pulmigen; Respibron; Sublingual antibacterial vaccine - Lallemand PharmaLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Lallemand Pharma
- Developer GlaxoSmithKline; Lallemand Pharma
- Class Antibacterials; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease; Respiratory tract infections
- Phase III Allergic asthma
Most Recent Events
- 01 Apr 2021 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Sublingual)
- 01 Mar 2019 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Sublingual) before March 2019 (GlaxoSmithKline pipeline, March 2019)
- 11 May 2017 Phase-III development for Allergic asthma (In adolescents, In children) is ongoing in Poland (Sublingual) (Lallemand Pharma website, May 2017)